Publications

Prevelance of Mupirocin Resistance in Staphylococcus spp. In the Asia-Pacific Region (2004; 2006-2008); A SENTRY Antimicrobial Surveillance Program Report, Lead author: Bell JM, presented at 7th annual International Symposium on Antimicrobial Agents and Resistance (ISAAR), March 18 – 20, 2009, Bangkok, Thailand

Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates. by Biedenbach DJ, Bell JM, Sader HS, Turnidge JD and Jones RN published in Antimicrob. Agents Chemother. 2009; 53 (3): 1260-1263

Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008. by Jones RN, Ross JE, Bell JM, Utsuki U, Fumiaki I, Kobayashi I and Turnidge JD published in Diagn. Microb. Infect. Dis. 2009; 65 (4): 404-413

Update on the in vitro activity of daptomycin tested against 17,193 Gram-positive bacteria isolated from European medical centers (2005-2007). by Sader HS, Moet GJ and Jones RN published in J. Chemother. 2009; 21 (5): 500-506

Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008) by Rhomberg PR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2009; 65 (4): 414-426

Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals. by Sader HS, Jones RN, Rossi KL and Rybak MJ published in J. Antimicrob. Chemother. 2009; 64 (5): 1024-1028

Linezolid surveillance program results for 2008 (LEADER Program for 2008). by Farrell DJ, Mendes RE, Ross JE and Jones RN published in Diagn. Microb. Infect. Dis. 2009; 65 (4): 392-403

First descriptions of bla_KPC in Raoultella spp. (R. planticola and R. ornithinolytica): Report from the SENTRY Antimicrobial Surveillance Program. by Castanheira M, Deshpande LM, DiPersio JR, Kang J, Weinstein MP and Jones RN published in J. Clin. Microb. 2009; 47 (12); 4129-4130

Daptomycin activity tested against linezolid-nonsusceptible Gram-positive clinical isolates. by Mendes RE, Jones RN, Deshpande LM, Ross JE, Sader HS published in Microb. Drug. Resist. 2009; 15 (4); 245-249

Expanded studies of piperacillin/tazobactam formulations: Variations among branded product lots and assessment of 46 generic lots. by Moet GJ, Watters AA, Sader HS and Jones RN published in Diagn. Microb. Infect. Dis. 2009; 65 (3): 319-322

Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008). by Sader HS and Jones RN published in Diagn. Microb. Infect. Dis. 2009; 65 (2): 158-162

Activity of daptomycin against Gram-positive bacterial isolates from Indian medical centres (2006-2007). by Mathai D, Biedenbach DJ, Jones RN, Bell JM, Turnidge JD and Sader HS published in Int. J. Antimicrob. Agents 2009; 34 (5): 497-499

Development of a disk diffusion method for testing Moraxella catarrhalis susceptibility using Clinical and Laboratory Standards Institute methods: a SENTRY Antimicrobial Surveillance Program report. by Bell JM, Turnidge JD, Jones RN published in J. Clin. Microb. 2009; 47 (7): 2187-2193

Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus arueus. by Sader HS, Rhomberg PR and Jones RN published in Antimicrob. Agents Chemother. 2009; 53 (7): 3162-3165

Activity of contemporary antifungal agents, including the novel Echinocandin Anidulafungin, tested against Candida spp., Cryptococcus Spp., and Aspergillus spp.: Report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007) by Messer SA, Moet GJ, Kirby JT, and Jones RN published in J. Clin. Microbiol. 2009; 47(6):1942-1946

Correlation of cefoxitin MICs with presence of mecA in Staphylococcus spp. by Swenson JM, Brasso WB, Ferraro MJ, Hardy DJ, Knapp CC, Lonsway D, McAllister S, Reller LB, Sader HS, Shortridge D, Skov R, Weinstein MP, Zimmer BL, Patel published in J. Clin. Microbiol. 2009; 47 (6): 1902-1905

Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: Results from the DECIDE Surveillance Program (2007) by Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect Dis. 2009; 64 (2): 177-184

ZAAPS International Surveillance Program (2007) for linezolid resistance: results for 5591 Gram-positive clinical isolates in 23 countries. by Jones RN, Kohno S, Ono Y, Ross JE and Yanagihara K published in Diagn. Microbiol. Infect. Dis. 2009; 64 (2): 191-201

Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respirator tract and skin and skin structures, including recent pharmacodynamic considerations. by Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2009; 64 (2):202-212

In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant Gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. by Vidaillac C, Leonard SN, Sader HS, Jones RN and Rybak MJ published in Antimicrob. Agents Chemother. 2009; 53 (6): 2360-2366

Dissemination of a bla_VIM-2-Carrying Integron Among Enterobacteriaceae species in Mexico: Report from the SENTRY Antimicrobial Surveillance Program. by Morfin-Otero R, Rodriguez-Nkoriega E, Desphande LM, Sader HS, Castanheira M published in Microbial. Drug Resistance. 2009; 15 (1): 33-35

TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens by Jones RN, Moet GJ, Sader HS, Mendes RE and Castanheira M published in J. Antimicrob. Chemother. 2009; 63 (4): 716-720

Clonal dissemination of two clusters of Acinetobacter baumannii producing OXA-23 or OXA-58 in Rome, Italy. by Mendes RE, Spanu T, Deshpande L, Castanheira M, Jones RN, Fadda G published in Clin. Microbiol. Infect. 2009; 15 (6): 588-592

Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: Coping with antimicrobial susceptibility in an era of resistance. by Weinstein MP, Klugman KP and Jones RN published in Clin. Infect. Dis. 2009; 48 (11): 1596-1600

Potency and bactericidal activity of iclaprim against Gram-positive isolates. by Sader HS, Fritsche TR and Jones RN published in Antimicrob. Agents Chemother. 2009; 53 (5): 2171-2175

In vitro potency of doripenem tested against an international collection of rarely isolated bacterial pathogens by Jones RN, Bell JM, Sader HS, Turnidge JD and Stilwell MG published in Diagn. Microbiol. Infect. Dis. 2009; 63 (4): 434-439

Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: Results from a global surveillance study (2003-2007). by Fritsche TR, Sader HS, Stillwell MG, Jones RN published in Diagn. Microbiol. Infect. Dis. 2009; 63 (4): 440-446

Antimicrobial activities of doripenem and other carbapenems against Pseudmonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp. by Castanheira M, Jones RN, Livermore DM published in Diagn. Microbiol. Infect. Dis. 2009; 63 (4): 426-433

Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents. by Mendes RE, Rhomberg PR, Bell JM, Turnidge JD, Sader HS published in Diagn. Microbiol. Infect. Dis. 2009; 63 (4): 415-425

Antimicrobial activity of daptomycin and selected comparators tested against bloodstream Staphylococcus aureus isolates from hemodialysis patients. by Sader HS, Fritsche TR, Jones RN published in Int. J. Infect. Dis. 2009; 13 (2): 291-295

In vitro activity of iclaprim and comparison agents tested against Neisseria gonorrhoeae including medium growth supplement effects. by Jones RN, Biedenbach DJ and Sader HS published in Diagn. Microbiol. Infect. Dis. 2009; 63 (3): 339-341

Carbapenem resistance among Pseudmonas aeruginosa strains form India: Evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18). by Castanheira M, Bell JM, Turnidge JD, Mathai D and Jones RN published in Antimicrob. Agents Chemother. 2009; 53 (3): 1225-1227

Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler’s diarrhea. by Fritsche TR, Biedenbach DJ and Jones RN published in Antimicrob. Agents Chemother. 2009; 53 (3): 1221-1224

Codetection of bla_OXA-23-like gene (bla_OXA-133) and bla_OXA-58 in Acintobacter radioresistens: Report from the SENTRY Antimicrobial Surveillance Program. by Mendes RE, Bell JM, Turnidge JD, Castanheira M, Deshpande LM and Jones RN published in Antimicrob. Agents Chemother. 2009; 53 (2): 843-844

A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp. by Diekema DJ, Messer SA, Hollis RJ, Boyken L, Tendolkar S, Kroeger J, Jones RN and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 2009; 233 (2): 233-236

Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemased among Acinetobacter spp. in Asia-Pacific nations: Report from the SENTRY Surveillance Program. by Mendes RE, Bell JM, Turnidge JD, Castanheira M, and Jones RN published in J. Antimicrob. Chemother. 2009; 63 (1): 55-59

Case report of Aurantimonas altamirensis bloodstream infection. by Mendes RE, Denys GA, Fritsche TR and Jones RN published in J. Clin. Microbiol. 2009; 47 (2): 514-515

Tigecycline In Vitro Susceptibility Test Accuracy Using Three Methods and USA-FDA Interpretive Criteria When Testing Japanese Clinical Isolates (2007), Lead author: Jones RN, presented at 48th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and 46th Annual Infectious Diseases Society of America (IDSA), October 25 – 28, 2008, Washington, DC

TR-700, a Novel Oxazolidinone, Tested Against Linezolid-Resistant Gram-positive Species with Well-Characterized Resistance Mechanisms, Lead author: Jones RN, presented at 48th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and 46th Annual Infectious Diseases Society of America (IDSA), October 25 – 28, 2008, Washington, DC

Novel Nanoemulsion Antimicrobials Tested Against Nine Gram-Positive Species, Lead author: Sutcliffe, presented at 48th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and 46th Annual Infectious Diseases Society of America (IDSA), October 25 – 28, 2008, Washington, DC

Antimicrobial Activity of Nanoemulsions Tested Against Seven Gram-Negative Species, Lead author: Fritsche TR, presented at 48th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and 46th Annual Infectious Diseases Society of America (IDSA), October 25 – 28, 2008, Washington, DC

Antimicrobial Characterization of CEM-101 Activity Against 331 Respiratory Tract Pathogens Including Multidrug-Resistant Pneumococcal Serogroup 19A (MDR-19A) Isolates, Lead author: Jones RN, presented at 48th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and 46th Annual Infectious Diseases Society of America (IDSA), October 25 – 28, 2008, Washington, DC

Antimicrobial Characterization of CEM-101: Activity Against Enterococci, Uncommon Gram-positive Pathogens, N. gonorrhoeae and Anaerobes, Lead author: Jones RN, presented at 48th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and 46th Annual Infectious Diseases Society of America (IDSA), October 25 – 28, 2008, Washington, DC

Antimicrobial Characterization of CEM-101: Potential Application Against Species Causing Enteritis/Gastroenteritis, Lead author: Jones RN, presented at 48th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and 46th Annual Infectious Diseases Society of America (IDSA), October 25 – 28, 2008, Washington, DC

Antimicrobial Characterization of CEM-101: PAE, Bactericidal Activity and Combinations, Lead author: Jones RN, presented at 48th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and 46th Annual Infectious Diseases Society of America (IDSA), October 25 – 28, 2008, Washington, DC

Antimicrobial Characterization of CEM-101: Single Step, Selection by Passaging and Inducible Resistances, Lead author: Jones RN, presented at 48th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and 46th Annual Infectious Diseases Society of America (IDSA), October 25 – 28, 2008, Washington, DC

Assessment of CEM-101 Susceptibility Testing Conditions and Optimization of Disk Diffusion Methods, Lead author: Jones RN, presented at 48th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and 46th Annual Infectious Diseases Society of America (IDSA), October 25 – 28, 2008, Washington, DC

Proposed Quality Control (QC) Parameters for Disk Diffusion (DD) Tests with Anidulafungin, Lead author: Jones RN, presented at 48th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and 46th Annual Infectious Diseases Society of America (IDSA), October 25 – 28, 2008, Washington, DC

Voriconazole Activity Against Aspergillus spp: Eight Years of Global Surveillance, Lead author: Diekema DJ, presented at 48th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and 46th Annual Infectious Diseases Society of America (IDSA), October 25 – 28, 2008, Washington, DC

Activity of Anidulafungin and Other Antifungal Agents: Results from an International Fungal Surveillance Program (2006-2007), Lead author: Fritsche TR, presented at 48th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and 46th Annual Infectious Diseases Society of America (IDSA), October 25 – 28, 2008, Washington, DC